Ƶ

Insulin Out-of-Stock; Yet Another GLP/GIP Agonist; Digital Diabetes Tools Worth It?

— News and commentary from the endocrinology world

Ƶ MedicalToday
Endo Break over a computer rendering of a man with illustrated body organs.

Both generic and branded formulations of 10-mL vials of insulin lispro injection (Humalog) will be through the start of April, Eli Lilly announced.

A new study , which has been declining in all countries, will continue to fall through the end of the century. (The Lancet)

In a phase I trial involving patients with obesity, an investigational, yielded up to a 3.3% average placebo-adjusted weight loss at day 28, and with low rates of gastrointestinal events, according to developer Viking Therapeutics. A phase II trial is scheduled for later this year.

Ten-year mortality risk was high for , data from the Netherlands showed. (JAMA Network Open)

More than half of patients with acromegaly on achieved an insulin-like growth factor 1 level ≤1.0 times the upper limit of normal compared with only 5% on placebo in the phase III PATHFNDR-2 study, Crinetics Pharmaceuticals said. The novel drug also met all secondary endpoints in the trial.

Digital diabetes management tools may not be , a new report from the Peterson Health Technology Institute suggested.

In a , one doctor wrote that metabolic bariatric surgery is "vastly" underused, given its excellent effectiveness and safety record.

A federal appeals court rolled back the Environmental Protection Agency's ability to . (Reuters)

In a cohort with severe male factor infertility, FDA-cleared FemaSeed helped 24% of in a pivotal trial, maker Femasys said.

From statins to inhalers to insulin, nonadherence is the undoing of many "forever" drugs; will ? (New York Times)

received a $15 million gift to further the treatment and study of endocrine disorders.

Some women are opting for in an effort to take some control over getting pregnant. (New York Times)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.